文献速递慢性肾脏病

不同eGFR范围内癌症结局的性别差异

Sex differences in cancer outcomes across the range of eGFR.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

Logistic回归分析晚期癌症就诊 odds,Cox模型分析全因死亡。结果显示eGFR<30与前列腺、乳腺和女性生殖器官晚期癌症就诊 odds 升高相关,且eGFR<30与全因死亡风险升高相关,女性中关联更强。

要点

  • eGFR<30与前列腺、乳腺和女性生殖器官晚期癌症就诊 odds 升高相关。
  • eGFR<30与两性全因死亡风险升高相关,女性中关联更强。
  • 多数癌症部位中,eGFR高低与晚期癌症就诊 odds 无显著关联。

核心结论

  • 多数癌症部位中,较低或较高eGFR与晚期癌症就诊 odds 无显著升高相关,但与生存率降低相关。
  • eGFR<30时女性全因死亡风险关联强于男性,值得进一步研究。

研究设计与样本

  • 采用Logistic回归模型分析基线eGFR与晚期癌症就诊 odds 的关系,采用Cox比例风险模型检验基线eGFRCr与全因死亡的关联。

主要发现

  • eGFR<30与前列腺、乳腺和女性生殖器官晚期癌症就诊 odds 升高相关,但与其他癌症部位无关。
  • 与eGFR>75-90相比,eGFR<30与两性全因死亡风险升高相关,女性中关联更强(女性HR 1.71,95%CI 1.56-1.88;男女比较HR 0.88,95%CI 0.78-0.99)。

临床怎么用

  • 对eGFR<30的癌症患者,尤其是女性,应关注全因死亡风险升高。
  • eGFR<30患者需警惕前列腺、乳腺和女性生殖器官晚期癌症就诊可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with chronic kidney disease (CKD) have increased incidence and mortality of most cancer types. We hypothesized that the odds of presenting with advanced cancer may vary according to differences in estimated glomerular filtration rate (eGFR), that this could contribute to increased all-cause mortality and that sex differences may exist. METHODS: Data were from Secure Anonymised Information Linkage Databank, including people with de novo cancer diagnosis (2011-17) and two kidney function tests within 2 years prior to diagnosis to determine baseline eGFR (mL/min/1.73 m2). Logistic regression models determined the odds of presenting with advanced cancer by baseline eGFR. Cox proportional hazards models tested associations between baseline eGFRCr and all-cause mortality. RESULTS: eGFR <30 was associated with higher odds of presenting with advanced cancer of prostate, breast and female genital organs, but not other cancer sites. Compared with eGFR >75-90, eGFR <30 was associated with greater hazards of all-cause mortality in both sexes, but the association was stronger in females [female: hazard ratio (HR) 1.71, 95% confidence interval (CI) 1.56-1.88; male versus female comparison: HR 0.88, 95% CI 0.78-0.99]. CONCLUSIONS: Lower or higher eGFR was not associated with substantially higher odds of presenting with advanced cancer across most cancer sites, but was associated with reduced survival. A stronger association with all-cause mortality in females compared with males with eGFR <30 is concerning and warrants further scrutiny.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Shemilt R, Sullivan MK, Hanlon P, et al. Sex differences in cancer outcomes across the range of eGFR. Nephrol Dial Transplant. 2024. PMID: 38460949. doi:10.1093/ndt/gfae059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。